Palau Pharma signs an exclusive option agreement with Sensorion Pharmaceuticals for the development of Palau´s histamine-4 receptor antagonist, UR-63325, for the treatment of vestibular disorders

Read

Laurent Nguyen joins Sensorion as Chief Executive Officer and Eric de La Fortelle joins its Board of Directors

Read

Next events